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Abstract: Approximately 40% of global HIV-1 transmission occurs in the female genital tract (FGT)
through heterosexual transmission. Epithelial cells lining the FGT provide the first barrier to HIV-1
entry. Previous studies have suggested that certain hormonal contraceptives or a dysbiosis of the
vaginal microbiota can enhance HIV-1 acquisition in the FGT. We examined the effects of lactobacilli and
female sex hormones on the barrier functions and innate immune responses of primary endometrial
genital epithelial cells (GECs). Two probiotic strains, Lactobacillus reuteri RC-14 and L. rhamnosus GR-1,
were tested, as were sex hormones estrogen (E2), progesterone (P4), and the hormonal contraceptive
medroxyprogesterone acetate (MPA). Our results demonstrate that probiotic lactobacilli enhance
barrier function without affecting cytokines. Treatment of GECs with MPA resulted in reduced
barrier function. In contrast, E2 treatment enhanced barrier function and reduced production of
proinflammatory cytokines. Comparison of hormones plus lactobacilli as a pre-treatment prior to
HIV exposure revealed a dominant effect of lactobacilli in preventing loss of barrier function by
GECs. In summary, the combination of E2 and lactobacilli had the best protective effect against HIV-1
seen by enhancement of barrier function and reduction in proinflammatory cytokines. These studies
provide insights into how probiotic lactobacilli in the female genital microenvironment can alter
HIV-1-mediated barrier disruption and how the combination of E2 and lactobacilli may decrease
susceptibility to primary HIV infection.
Keywords: HIV-1; probiotic; estrogen; progesterone; genital epithelial cells; barrier
1. Introduction
Currently, women account for more than 50% of people infected with HIV-1 (human
immunodeficiency virus-1) worldwide [1]. Globally, the number of new HIV-1 infections reported
in women has risen continuously over the past few decades and women have been shown to be
at an increased risk of HIV-1 infection compared to men [1]. Infection in women occurs primarily
through heterosexual transmission in the female genital tract (FGT) with early mechanisms still not
well understood [2].
Although the etiology of greater acquisition within the FGT is not fully understood, increased
inflammation in the FGT has been suggested as a common theme associated with higher rates of
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transmission [3–7]. The FGT can be divided into two distinct compartments. The lower FGT consists of
the vagina and the ectocervix and is protected by multiple layers of stratified squamous epithelium.
In contrast, the upper FGT consists of the endocervix, uterus, fallopian tubes and ovaries, and is lined by
a single layer of columnar epithelium connected by tight junction proteins. Although the tight junctions
help to strengthen the epithelium, the upper FGT is still vulnerable to HIV infection, as it is composed
of a single layer of cells, thus placing the virus in closer proximity to target cells beneath the epithelial
layer. Studies have demonstrated that upper genital tract, especially the transition zone between ecto
and endo cervix is highly susceptible to HIV-1 infection [3,8,9]. In order for HIV-1 to establish successful
infection, the virus must cross the epithelial barrier in order to access target cells [10]. Previous studies
have demonstrated that the HIV-1 surface glycoprotein-120 (gp120) directly interacts with primary
human genital epithelial cells (GECs), leading to the production of proinflammatory cytokines, including
tumor necrosis factor-alpha (TNF-α). This production decreases GEC barrier integrity and subsequent
microbial translocation of HIV-1 across the upper female genital tract epithelium [11,12].
A significant body of research has suggested that female sex hormones, progesterone (P4)
and estrogen (E2), play a role in HIV-1 infection in women, as they have been shown to regulate
innate immunity and inflammation in the FGT [4,13–16]. Furthermore, over 100 million women
globally use hormonal contraceptives (HCs) [17] and a growing body of literature suggests there
may be an increased risk of HIV-1 acquisition caused by use of injectable HCs [18–20]. Of particular
interest is the progestin-based HC, Depot medroxy-progesterone acetate (DMPA or Depo-Provera).
The low cost, long-term effectiveness of DMPA as a contraceptive makes it an attractive choice for
women. Notably, DMPA is most often used in the developing world, especially in regions such as
sub-Saharan Africa, where HIV-1 prevalence is at its highest. Human epidemiologic studies have
shown an association between DMPA use and increased HIV-1 infection, disease progression and
mortality [21,22]. Additionally, several meta-analyses have examined the strength of the evidence in
light of conflicting evidence regarding the use of HCs and HIV-1 acquisition [19–21,23]. One such
analysis found that DMPA increased women’s risk of contracting HIV-1 by 40 percent compared to
those not using the contraceptive [19]. This was confirmed in two further meta-analyses showing a 49
and 40 percent increased risk of HIV-1 acquisition with DMPA use [23–25]. Although associations have
been observed between the use of injectable HCs and increased HIV-1 susceptibility, the pathways
involved in these outcomes remain unclear and are under-investigated.
In addition to hormones, the microbiota of the FGT has been correlated with alterations in HIV-1
susceptibility. The composition of the microbiota within the FGT influences HIV-1 susceptibility and
may be regulated by female sex hormones [13,25,26]. Molecular studies have identified more than 250
microbial species capable of growth within the vaginal tract [27]. A decreased abundance of microbial
species has also been identified in upper genital tract [28]. Factors such as age, ethnicity, female sex
hormones and use of HC have been shown to affect the composition and relative abundance of these
species [29]. In the majority of women, a ‘healthy’ FGT microbiota is characterized by the abundance
of Lactobacillus species, mainly, L. crispatus, L. jensenii, L. gasseri and/or L. iners [28,30]. However, when
the composition of the microbiota is shifted toward polymicrobial species and increased bacterial
diversity, it is associated with bacterial vaginosis (BV) [27]. A decrease in Lactobacillus dominance
and increased diversity is commonly associated with increased susceptibility to STIs including HIV-1,
HSV-2, gonorrhea, and Chlamydia [31,32]. In comparison, a Lactobacillus-rich environment exerts
protective effects against urogenital diseases, including, BV, yeast infections, HSV-2, and HIV-1 [33].
Interestingly, it has been suggested that the menstrual cycle may be associated with changes in the FGT
microbiota [13]. Cyclic changes observed with the differing phases of the menstrual cycle may involve
factors such as hormones, pH and glycogen content, bacterial adherence, their ability to colonize
epithelial cells, and the composition of microbial species [34,35].
The concept of applying probiotic lactobacilli to the vagina to displace pathogens and improve
host defenses dates back to the mid-1980s but has more recent interest [34]. The most documented
probiotic strains for urogenital application, L. rhamnosus (GR-1) and L. reuteri (RC-14), were selected for
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testing in these studies due to these and other attributes, and their benefits were shown in a series
of clinical studies. These include showing that the acid produced by both strains could kill HIV [35],
and the instillation of GR-1 into the vagina up-regulated host defenses and barrier function [36].
Since the upper genital tract epithelial barrier is most susceptible to HIV-1, the aim of this study
was to examine the interactions between these epithelial cells, sex hormones and probiotic strains of
bacterial in the context of HIV-1 infection. The results reveal that a combination of lactobacilli and
estrogen provides both enhanced barrier function and reduced proinflammatory cytokine production
by GECs in response to HIV-1.
2. Materials and Methods
2.1. Isolation and Culture of Primary Genital Tract Epithelial Cells
Primary genital epithelial cells were isolated from cervical and endometrial tissues obtained from
women aged 30–59 years (mean age 42.9 ± 7.2) undergoing hysterectomies for benign gynecological
reasons at Hamilton Health Sciences Hospital. Informed written consent was obtained in accordance
with the approval of the Hamilton Integrated Human Research Ethics Board. A detailed protocol for
the isolation and culture of primary GECs has previously been described by Kaushic et al., [26]. Briefly,
endometrial or endocervical tissues were minced into small pieces, digested in an enzyme mixture for
an hour at 37 ◦C. GECs were isolated by a series of separations through nylon mesh filters (Small Parts,
Miramar, FL, USA), resuspended in DMEM/F12 primary growth medium (Invitrogen, Burlington, ON,
Canada), and seeded onto Matrigel-coated (BD Biosciences, Mississauga, ON, Canada) tissue culture
inserts (BD Biosciences). GEC cultures were grown for 5–7 days until confluent monolayers were
formed. The confluency was monitored by transepithelial resistance (TER) measured by a volt ohm
meter (EVOM; World Precision Instruments, Sarasota, FL, USA). Confluent monolayers showing TER
values greater than 1000 Ω/cm2 were used for further experiments. The purity of epithelial monolayers
was between 95% and 98%, with no trace of any hematopoietic cells.
2.2. Hormone and Contraceptive Treatment
Sex hormones E2 (10−3 M), P4 (10−4 M) (purchased as water-soluble products, Sigma Aldrich,
Oakville, ON, Canada), or MPA (10−3 M) (Sigma Aldrich) were prepared as stock in either water
(E2, P4) or 100% ethanol (MPA) and diluted to the final working concentrations 10−9 M, 10−7 M and
10−9 M, respectively, in phenol-red–free Dulbecco’s modified Eagle’s medium/F12 (Life Technologies,
Burlington, ON, Canada), the primary cell media [37]. The final dilution of ethanol in the primary
cell medium was 10−6 fold. Sex hormone concentrations correspond to highest serum levels during
menstrual cycle.
2.3. Treatment of GECs with Lactobacilli and HIV-1 Exposure
The probiotic Lactobacillus reuteri RC-14 and Lactobacillus rhamnosus GR-1 were provided by
Dr Gregor Reid, Lawson Health Research Institute, London, Ontario [35]. Both strains were grown
anaerobically in MRS broth (VWR, Mississauga, ON, Canada) at 37 ◦C. Prior to the addition of bacteria
to GECs, the RC-14 and GR-1 were washed to remove the MRS medium. The bacteria were then
re-suspended in primary cell culture medium and added to the GEC monolayers at a concentration of
100 CFU/cell. Following 2 h of incubation, unattached bacteria was removed, and the GEC monolayers
were washed with PBS and fresh medium was added.
HIV-1 virus strain ADA (M-tropic) was propagated by infection of adherent monocyte derived
macrophages isolated from human PBMCs, followed by concentration of the virus using the Amicon
Ultra-15 filtration system (Millipore, Billerica, MA, USA). Viral stocks were titered for infectious viral
units per milliliter using the TZM-bl indicator cell assay as previously described [38]. HIV-1 was
added as 105 infectious units in 100 µL quantity on apical side of confluent GEC cultures. GECs were
incubated with virus for 24 h.
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2.4. Fluorescein Isothiocyanate (FITC)-Dextran Dye Assay for Cell Monolayer Permeability Assay
FITC-dextran (4 kDa; 2.3 mg/mL; Sigma-Aldrich) was added to the apical surface of GECs
immediately after bacteria, or during HIV incubations, and cells were incubated for 24 h, after which
50 µL of basolateral medium was sampled and placed in duplicate in a 96 well plate. FITC fluorescence
was measured using a microplate reader (SpectraMax i3, Molecular Devices, Sunnyvale, CA, USA) at
an excitation of 490 nm and emission of 520 nm. The FITC-dextran in the basolateral compartment is
expressed as a percentage of FITC-dextran added to the apical compartment.
2.5. Cell Stress and Cytotoxicity Measured by Lactate Dehydrogenase Release
Lactate dehydrogenase (LDH) enzyme was detected in the supernatants using an LDH kit (Pierce,
Thermo Scientific, San Jose, CA, USA) according to manufacturer instructions.
2.6. Magpix Multi-Analyte Assay for Measurement of Cytokines and Chemokines
Supernatants from GEC cultures were collected at various time points following exposure to
hormones, Lactobacillus strains GR-1 or RC-14, or HIV-1. The Magpix multi-analyte magnetic bead-based
assay was used to measure the concentrations of cytokines and chemokines including TNF-α, IL-1α,
IL-8 and RANTES in supernatants, using the Magpix technology system (Millipore, Billerica, MA,
USA), as per the manufacturer’s instructions.
2.7. Immunofluorescent Staining of Epithelial Cell Cultures
After treatment with lactobacilli, hormone and/or HIV-1, GECs were fixed in 4% paraformaldehyde
(PFA; Electron Microscopy Sciences, Hatfield, PA, USA), permeabilized, and stained for ZO-1,
and immunofluorescence microscopy was performed, as previously described [11]. Images were
acquired using an inverted laser-scanning microscope (Olympus, FLUOVIEW FV3000) equipped
with argon laser (450 to 514 nm). Immunoreactive ZO-1 were excited using the 488-nm laser and
collected using a standard fluorescein isothiocyanate filter set. An x63 oil immersion objective lense
with 2X zoom was used. For each experiment, image acquisition (i.e., confocal microscope settings)
and processing was identical between controls and treated cells. Images are presented en face to
illustrate the distribution of the tight junction protein stained by Alexa Fluor 488 secondary antibodies
(green). Fluorescence measurement on three different images of same treatment were analyzed by
image analysis software (Image J version 1.50i, NIH) to measure the areas of fluorescently stained ZO-1.
2.8. Statistical Analysis
Statistical analysis and graphical representation were performed using Prism 6.0d software
(GraphPad Software). A one-way analysis of variance (ANOVA) using the Bonferonni post-test
was also used for analysis of data from all experiments. When comparing two treatment groups,
an unpaired t-test was used for analysis.
3. Results
3.1. Exposure to Probiotic Strains of Lactobacilli Improves the Barrier Function of Primary Upper Genital Tract
Epithelial Cells
The relationship between upper genital tract epithelial cells and lactobacilli with respect to barrier
function has not been well characterized. To study the interaction of the probiotic lactobacilli strains
L. rhamnosus (GR-1) and L. reuteri (RC-14) with GECs, we exposed confluent monolayers of primary
human endometrial epithelial cells to each bacterial strain and assessed barrier function by measuring
transepithelial electrical resistance (TER) and leakage of FITC-dextran. The two strains of lactobacilli
were added for 2 h, non-adherent bacteria were removed, and fresh medium was added. After a further
24 h of culture, barrier function was assessed by FITC-dextran leakage and TER, a measure of cell
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monolayer integrity that is commonly used as a proxy indicator to monitor the growth and condition of
polarized monolayers [36]. The presence of either probiotic lactobacilli strains significantly increased
TER of GEC monolayers in comparison to the no bacteria control, indicative of an enhancement in the
integrity of the GEC monolayer (Figure 1A). Epithelial cell monolayer permeability to FITC-dextran is
an additional measure of GEC barrier function [36]. Since the TER of GECs increased in the presence of
probiotic lactobacilli, permeability was then measured to assess the ‘leakiness’ of the GEC monolayers.
The 4 kDa, fluorescent FITC-dextran dye was added to the apical compartment of the GEC monolayer
and the amount of dye that leaked to the basolateral compartment was measured 24 h later. There
was a significant decrease in FITC-dextran that leaked to the basolateral compartment beneath the
GEC monolayers treated with probiotic lactobacilli, compared to the control cultures without bacteria
(Figure 1B). Both decrease in permeability and the increase in TER indicates that probiotic lactobacilli
were able to enhance GEC barrier functions.
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Figure 1. Exposure to probiotic strains of lactobacilli improves barrier function of primary genital
epithelial cells and does not alter viability or production of pro-inflammatory cytokines and chemokines.
Confluent monolayers of GECs were treated for 2 h with probiotic strains L. rhamnosus GR-1 and L. reuteri
RC-14 abbreviated GR-1 and RC-14 respectively and/or no bacteria (Ctrl). After treatment, non-adherent
lactobacilli were removed, and GECs were monitored for a further 24 h. (A) TER was measured
pre-treatment and at 24 h post-treatment with lactobacilli. TER is expressed as percent of pre-treatment
TER. (B) Following treatment with bacteria, primary GECs were incubated with FITC-dextran dye on
the apical surface, and FITC-dextran leakage in the basolateral compartment was measured after 24 h.
Data are expressed as a percentage of FITC-dextran added to the apical compartment. (C) LDH release
(Abs490) by GECs 24 h after treatment with GR-1, RC-14 or no bacteria, or from GEC cultures lysed to
release total LDH (positive control). (D–G) 24 h post-treatment with lactobacilli, cell supernatants were
collected and analyzed for the presence of TNF-α, IL-1α, IL-8, and RANTES. Dashed line indicates assay
limit of detection. Data shown are representative of 6–9 separate experiments done on tissues taken
from 6-9 different donors and shown as mean ± SEM. Each experiment had 3 replicate cultures for each
experimental condition. Statistical significance is indicated as: **** p < 0.0001, *** p < 0.001, ** p < 0.01.
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Lactate dehydrogenase (LDH) is released into the supernatant when cell membrane integrity
is compromised and measured in culture supernatants as an indicator of cellular cytotoxicity and
cytolysis [39]. LDH was only present in a small amount in GEC monolayers treated with the probiotic
lactobacilli compared to lysed GEC cultures. No significant differences in LDH production were
observed between the control treatment (no bacteria added) and cells exposed to probiotic bacteria
strains (Figure 1C). This suggests that the presence of probiotic bacterial strains, GR-1 and RC-14,
do not adversely affect GEC viability.
Exposure to bacteria such as Lactobacilli may result in the production of cytokines and chemokines
by GECs, thereby altering the local tissue immune environment that would impact response to
pathogens. To assess the effect of lactobacilli on innate mediators of inflammation produced by GECs,
we measured the production of the proinflammatory cytokines (TNF-α, and IL-1α) and the chemokines
IL-8 and RANTES following lactobacilli treatment. Treatment with GR-1 and RC-14 did not significantly
alter production of TNF-α, IL-1α, IL-8 or RANTES when compared to untreated GECs indicating that
these strains of lactobacilli do not influence cytokines or chemokines produced by cultured GECs
(Figure 1D–G). Baseline cytokine levels were found to vary between different tissue samples, but in all
tissues, cytokine trends were found to be the same after treatments.
3.2. Estrogen Enhances Barrier Function and Modulates Proinflammatory Cytokine and Chemokine Response in
Primary GECs
Many studies have demonstrated that female sex hormones regulate immune responses in the
FGT [40], however the response of GECs to these hormones remain unclear. Epithelial cells in the FGT
are under constant regulation by fluctuations of the sex hormones, E2 and P4, during the menstrual
cycle. Additionally, hormonal contraceptives, such as MPA, influence the menstrual cycle and alter
the natural hormone regulation, which may affect the function of the GECs. To better understand the
role of sex hormones in the FGT, we examined how E2, P4, and MPA influence the FGT epithelial
barrier functions and modulate epithelial proinflammatory responses. GECs grown in the presence
sex hormone E2 showed significant increase in TER while cells grown in presence of MPA displayed
significantly lower TER values compared to other treatments over time (Figure 2A). GECs treated with
MPA or P4 also displayed an increase in permeability to FITC-dextran, compared to E2 and no hormone
control GECs (Figure 2B). Leakage in the MPA treated monolayers was the highest of all treatments.
To ensure that the increase in permeability and decrease TER values of GECs treated with MPA was
not due to decreased viability, LDH released by GECs was measured in supernatants from all treatment
groups (Figure 2C). In comparison to the control of directly lysed non-treated GECs, the E2, P4, MPA
and no hormone GECs demonstrated significantly less release of LDH. No significant differences were
observed between the MPA treated cells and E2, P4, and no hormone. GECs grown in the presence
of E2 showed a significant decrease in TNF-α, IL-1α, and IL-8 production compared to no hormone
treated cells, indicating that E2 was conferring an anti-inflammatory environment (Figure 2D–F).
While cells treated with P4 or MPA showed significant reduction in IL-1α production, there was no
significant reduction in TNF-α or IL-8 production by those cells. None of the treatment groups had
significant changes in RANTES production, although the MPA-treated group showed the highest levels
of RANTES production.
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3.3. Pre-Exposure of GECs to Probiotic Lactobacilli Prevents HIV-1-Mediated Barrier Disruption and
Downregulates Proinflammatory Cytokine Production by GECs
A Lactobacillus rich environment has been shown to exert protective effects against urogenital
diseases, including BV, yeast infection, HSV-2, and HIV-1 [33]. To further elucidate the mechanisms
by which lactobacilli confer protection against HIV-1 infection, we exposed GECs to HIV-1 following
pre-treatment with probiotic strains of lactobacilli. HIV-1 exposure alone resulted in reduced TER.
However, this decrease was reversed in GEC cultures exposed to HIV-1 after pre-treatment with
either of the two strains of lactobacilli (Figure 3A,B). Likewise, GECs treated with probiotic lactobacilli
followed by HIV-1 had significantly decreased FITC-dextran dye leakage when compared to GECs
treated with HIV-1 alone (Figure 3C,D). Together this data suggests that prior exposure to probiotic
lactobacilli can prevent GEC barrier dysfunction caused by HIV-1 [11].
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We then examined the effect of pre-exposure to lactobacilli on the proinflammatory cytokines
TNF-α, IL-1α, IL-8 and RANTES produced by HIV-1 exposed GECs. Pre-treatment with GR-1 and
RC-14 significantly reduced HIV-1-mediated induction of TNF-α (Figure 3E). A similar effect was
observed for IL-1α, although the increase in production of this cytokine in response to HIV-1 did not
reach statistical significance (Figure 3F). In contrast, production of IL-8 by GECs was unaffected by HIV-1
exposure and remained unaltered following pre-exposure to probiotic lactobacilli (Figure 3G). RANTES
production was significantly increased by GECs treated with HIV-1 alone. However, pre-treatment
with either probiotic lactobacilli resulted in significant reduction in RANTES production, although at
levels still above that of the untreated control (Figure 3H). Thus, prior exposure to probiotic lactobacilli
appeared to reduce production of some proinflammatory cytokines by GECs in response to HIV-1.
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Figure 3. Probiotic strains of lactobacilli ameliorate HIV-1-mediated barrier disruption and
downregulate proinflammatory cytokine production by GECs. GECs were treated for 2 h with
probiotic strains L. rhamnosus GR-1 and L. reuteri RC-14 abbreviated GR-1 and RC-14 respectively or no
bacteria (Control). Following treatment, various cultures of GECs were then exposed to HIV-1 or no
virus (Mock) and monitored for 24 h. (A,B) TER values were observed pre- and 24 h post-HIV-1 exposure.
TER is expressed as percent of TER measured before HIV-1 exposure. (C,D) Following treatment with
lactobacilli and during viral exposure, GEC cultures were treated apically with FITC-labeled dextran
dye. At 24 h, 50 µL of basolateral were collected and fluorescence was measured using a microplate
reader. The dextran leakage in the basolateral compartment is expressed as a percentage of dextran
added to the apical compartment. (E–H) 24 h post-exposure to HIV-1, cell supernatants were collected
and analyzed for TNF-α, IL-1α, IL-8, and RANTES. Dashed line indicates assay limit of detection.
Data shown is representative of 6–9 separate experiments done on cells isolated from 6–9 different
tissues, each experiment had 3 replicate cultures for each experimental condition. Data is plotted as
mean + SEM. Statistical significance is indicated: **** p < 0.0001, *** p < 0.001, ** p < 0.01, * p < 0.05.
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3.4. Estrogen Pre-Treatment Prevents Leakage and Decreases TNF-α Production but not RANTES Production
Induced by HIV-1
Several studies using animal models or ex vivo cervical explants have shown that E2 plays a
protective role in HIV-1 infection, while P4 increases susceptibility to HIV-1 [41,42]. Furthermore,
an increased susceptibility to sexually transmitted infections (STIs) including HIV-1 has been reported
in women using the hormonal contraceptive DMPA [8,21,22,43]. The effect of E2 and MPA on the
GEC barrier, and modulation of immune responses as a mechanism of altered susceptibility to HIV-1,
requires further investigation. Therefore, we grew GECs in the presence or absence of E2, P4 or
MPA and then exposed the cells to HIV-1. Exposure of GECs to HIV-1 significantly decreased TER
irrespective of prior hormonal treatment (Figure 4A). GECs grown in the absence of hormone, or the
presence of P4 or MPA, showed a significant increase in FITC-dextran leakage after exposure to HIV-1
(Figure 4B). However, no significant increase in FITC-dextran leakage was observed in GECs grown in
the presence of E2 and then exposed to HIV-1. Prior treatment with MPA appeared to increase the
effects of HIV-1 on FITC-dextran leakage (Figure 4B).
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Figure 4. Estrogen treatment prevents HIV-1-mediated barrier disruption in GECs. GECs were grown
in the absence (NH) or presence of sex hormones E2, P4 or MPA until confluence was reached. GECs
were then exposed to HIV-1 and monitored for 24 h. (A) TER values were observed at 0 h and 24 h
after HIV-1 exposure and expressed as percent of pre-treatment TER. Data is derived from 3 separate
GEC culture experiments, with a minimum of two replicates per experimental condition were included.
(B) FITC-dextran leakage to basolateral compartment after 24 h exposure to HIV-1. The FITC-dextran
leakage is expressed as a percentage of FITC-dextran added initially. (C–F) 24 h post HIV-1 exposure,
cell supernatants were collected and analyzed for TNF-α, IL-1α, IL-8 and RANTES. Dashed line
indicates assay limit of detection. Representative data is shown from 5–8 separate experiments done on
cells isolated from 5–8 different tissues obtained from different donors; each experiment had 3 replicate
cultures for each experimental condition. Data is plotted as mean + SEM. Statistical significance is
indicated: **** p < 0.0001, *** p < 0.001, ** p < 0.01, * p < 0.05.
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GECs grown in the absence of hormones or pre-treated with P4 showed a significant increase in
TNF-α after exposure to HIV-1, whereas pre-treatment with E2 and MPA resulted in reduced response
to HIV-1 (Figure 4C). A statistically significant reduction in production of IL-1α was observed for GECs
treated with E2 and MPA compared to no hormone in response to HIV-1 (Figure 4D). No significant
increase in IL-8 production by GECs following HIV-1 exposure was observed in the absence or presence
of hormones (Figure 4E). However, prior treatment with MPA resulted in a significant increase in IL-8
production after HIV-1 exposure. Finally, production of RANTES was examined. Regardless of the
presence or absence of E2, P4 or MPA, exposure of GECs to HIV-1 resulted in significant increase in the
production of RANTES (Figure 4F).
3.5. Probiotic Lactobacilli and Estrogen Prevent HIV-1-Mediated Epithelial Barrier Disruption
The results described thus far indicate that both E2 and probiotic lactobacilli reduce the adverse
effects of HIV-1 on GEC barrier function and production of proinflammatory cytokines. Next we
examined how the combination of probiotic lactobacilli with E2, P4 or MPA would alter the response
of GECs to subsequent HIV-1 exposure. GECs were grown to confluence in the presence or absence of
E2, P4, and MPA, then treated with the probiotic RC-14, and exposed to HIV-1. Compared to HIV-1
exposure alone, TERs for GECs exposed to probiotic lactobacilli reached levels equal to control GECs
that had no exposure to HIV-1. In contrast, GECs treated with or without hormones and challenged
with HIV-1 had significantly reduced TER (Figure 5A). The probiotic lactobacilli treatment had a
positive effect on the TER of GECs exposed to HIV-1 regardless of prior exposure to no hormone,
E2 or P4 (Figure 5A). As a further assessment of barrier permeability, pre-treatment with RC-14 prior
to HIV-1 exposure abrogated the HIV-1-mediated increase in FITC-dextran leakage in no hormone,
P4 and MPA treated GECs (Figure 5B).
Pre-treatment with RC-14 significantly reduced HIV-1-mediated induction in TNF-α and IL-1α
in the presence of no hormone or P4 (Figure 5C,D). GECs grown in the presence of E2 and MPA and
pre-treated with RC-14 did not show a significant decrease in TNF-α compared to HIV-1 exposure
alone (Figure 5C). However, it should be noted that in the presence of E2 or MPA, HIV-1 did not induce
a significant TNF-α response in comparison to the no treatment control or P4 (Figure 5C). This indicates
that the effect of probiotic lactobacilli on HIV-1-mediated increases in TNF-α is only demonstrated
clearly when GECs are pre-treated with P4. In contrast, a significant increase in production of IL-8 was
only observed in HIV-1 exposed cells that had previous exposure to MPA (Figure 5E). In GECs grown
in MPA, the added treatment with RC-14 resulted in reduced IL-8 response to HIV-1, indicating that
probiotic lactobacilli could reverse the effects of MPA alone. There was a significant increase for all
hormonal conditions in response to HIV-1 alone. However, pre-treatment with RC-14 lactobacilli prior
to HIV-1 exposure significantly reduced the HIV-1-mediated increase in RANTES production for all
hormone treatment groups (Figure 5F).
In order to confirm the changes in GEC monolayer TER and permeability, we performed fluorescent
staining for the tight junction protein ZO-1 with visualization by confocal microscopy (Figure 6).
Representative images and quantitative results shown in Figure 6 indicate that there is a decrease in
ZO-1 observed after HIV-1 treatment of GECs that were pre-treated with no hormone or with P4 or
MPA. GECs grown in the presence of E2 and exposed to HIV-1 showed reduced impairment of ZO-1
expression. Furthermore, pre-treatment with RC-14 prior to HIV-1 exposure shows a maintenance of
ZO-1 lattice structure compared to hormone with HIV-1 exposure alone.
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Figure 5. Probiotic lactobacilli and estrogen ameliorate HIV-1-mediated barrier disruption. GECs were
grown in the absence of hormone (NH) or with E2, P4 or MPA until confluence was reached. Primary
GEC cultur s were tr ated for 2 h with L. reuteri RC-14 or medium control (Mock). After l ctob illi
treatment GECs were exposed to HIV-1 and monitored for 24 h. (A) TER values were observed at 0 and
24 h post-viral exposure and expressed as percent of pre-treatment TER. (B) During viral exposure,
primary GECs were incubated with an apical treatment of FITC-dextran dye for 24 h. The FITC-dextran
leakage into the basolateral compartment is expressed as a percentage of total FITC-dextran added
to the apical compartment. (C–F) 24 h following HIV-1 exposure, cell supernatants were collected
and analyzed for TNF-α, IL-1α, IL-8, and RANTES production. Dashed line indicates assay limit of
detection. Data are representative of 5–8 experiments from 5–8 different tissues, each tissue obtained
from a separate donor. Each experiment had 3 replicate cultures for each experimental condition. Data
is plotte as mea + SEM. Statistical significance is indicated: **** p < 0.0001, *** p < 0.001, ** p < 0.01,
* p < 0.05.
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Figure 6. Probiotic lactobacilli and estrogen protect GECs from HIV-1-mediated tight junction
degradation. GECs were grown in the presence or absence (NH) of E2, P4 or MPA until confluence
was reached. Confluent GECs were pre-treated for 2 h with L. reuteri (RC-14) at 100 CFU/cell or no
bacteria. After pre-treatment, non-adherent lactobacilli were removed, and primary GEC were exposed
to HIV-1. After 24 h, cells were fixed and stained for ZO-1 tight junction proteins. Images were
captured with Olympus confocal microscope. Representative images (×1260 magnification) of each
culture condition are shown (A). Fluorescence of 3 different images taken for each culture condition
(see Methods for details) and were measured by Image J software (B). Data is plotted as mean + SEM of
relative fluorescence. Statistical significance is indicated: **** p < 0.0001, *** p < 0.001, ** p < 0.01.
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4. Discussion
The results presented here indicate that irrespective of hormonal conditions, two probiotic
lactobacilli strains enhanced GEC barrier function and diminished the proinflammatory mediators
produced by GECs in response to HIV-1 exposure. Among the hormones we tested, E2 and MPA
demonstrated reduced production of proinflammatory cytokines and chemokines by GECs, an effect
that was sustained even after HIV-1 exposure. However, the attenuating effect of E2 and MPA was not
evident for production of the proinflammatory chemokine RANTES, suggesting that these cytokines
and chemokines may have differential pathways of regulation. The increase in barrier function
observed with lactobacilli treatment and the decrease of inflammation observed in the presence of
E2 indicate that their combination may create an environment within the FGT that is important for
protection against HIV-1.
An inflammatory environment in the FGT is associated with a disruption in epithelial barrier
function, which increases permeability between adjacent cells allowing microbial translocation of
HIV-1 [11,44], and elevates production of proinflammatory TNF-α, causing further barrier damage [11].
Previous literature has indicated that both lactobacilli and E2 have beneficial effects in the FGT and
have been implicated in protection against HIV-1 [8]. However, whether these beneficial effects are
mediated through their effects on the mucosal epithelial cells lining the upper genital tract is unclear.
Therefore, we undertook this study to examine the direct effects of probiotic lactobacilli, hormones or
HC on the response of GECs prior to and post-HIV-1 exposure.
Given that both inflammation and a decrease in barrier function are associated with increased
HIV-1 acquisition and disease progression [11,44–46], we sought first to explore the role of hormones,
hormone-based contraceptives and lactobacilli on the barrier functions of primary cultures of human
GECs. Using our GEC culture system, we showed that probiotic strains of lactobacilli (GR-1 and C-14)
significantly increased TER, a measure of barrier integrity (Figure 1A) and significantly decreased
barrier permeability (Figure 1B). The sex hormone E2 enhanced barrier integrity but did not reduce
barrier permeability, whereas treatment with MPA reduced integrity and increase barrier permeability.
This ability to enhance barrier functions could explain why a lactobacilli-dominated vaginal ecosystem
is protective against pathogens such as HIV-1, and why application of probiotic strains may offer this
same advantage.
The presence of either strain of Lactobacillus in the absence of HIV-1, did not result in any change
in production of TNF-α, IL-1α, IL-8 or RANTES by GECs. On the other hand, sex hormone E2 exerted
a significant anti-inflammatory effect on GECs, as seen by a reduction in the secretion of TNF-α, IL-1α,
and IL-8 (Figure 2), whereas P4 and MPA had significant effects on reducing IL-1α alone. Neither
E2, P4 nor MPA altered RANTES production by GECs. The overall suppressive activity of E2 and
its selective ability to reduce TNF-α, a cytokine well known for its ability to induce barrier damage,
indicates E2 could have a dominant effect in reducing local inflammation. Given that inflammation is a
known contributor to STI acquisition in the FGT, the presence of E2 may play a protective role against
some pathogens.
The finding that probiotic lactobacilli can increase epithelial barrier function agrees with studies of
both intestinal and genital tract systems [47,48]. The ability of lactobacilli to reduce pathogen-induced
inflammation also aligns with other studies [47,49]. Interestingly, anti-inflammatory effects are also
conferred by the lactic acid these strains produce [48]. By lactobacilli application strengthening these
host defenses, relatively quickly (within two hours) making it more difficult for HIV-1 to translocate
the GECs, it suggests a practical means by which women might be able to reduce their risk of infection.
Although lactobacilli had no direct effect on GECs in regard to their normal production of inflammatory
cytokines and chemokines (Figure 1), pre-treatment with lactobacilli did greatly reduce that production
of TNF-α, IL-1α, and RANTES in response to subsequent HIV-1 challenge (Figure 4). Thus, a relatively
brief exposure (2 h) to probiotic lactobacilli primes GECs to increase barrier function and reduce their
inflammatory mediator response to HIV-1, indicating a key role for these common FGT bacteria in
conferring resistance to HIV infection.
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Estrogen has been applied directly to the vagina of post-menopausal women for many years.
Studies showed it can reduce the incidence of recurrent urinary tract infection and increase production
of antimicrobial lacto-transferrin in the vagina [49,50]. The present study showed that E2 can increase
barrier function as well as decrease production of proinflammatory TNF-α and IL-1α (Figure 2).
A proinflammatory environment in the FGT, including increased IL-1α and IL-1β, has been associated
with BV and increased acquisition of STIs [50]. By countering TNF-α that is released in response to
HIV-1 and the damage it causes to the integrity of the epithelial cell barrier, it may be possible for
estrogen to interfere with translocation of HIV-1 across the epithelium [11]. This is supported by E2
significantly reducing leakage by GEC cultures and TNF-α and IL-1α production when challenged
with HIV-1. In contrast, the apparent dichotomous observation of greatly increased barrier dysfunction
and leakage along with decreased TNF-α and IL-1α production after treatment with MPA and HIV-1
challenge indicate that MPA may still lead to enhanced HIV-1 infection due to increased viral entry.
Regardless of hormone (E2 vs. P4) pre-treatment, the addition of L. reuteri RC-14 improved barrier
integrity (TER) in GECs challenged with HIV-1 indicating that this barrier enhancement was largely
dominated by the effects of lactobacilli (Figure 6). Likewise, HIV-1 mediated induction of TNF-α and
IL-1α was greatly reduced by the combination of E2 or MPA with RC-14.
The exact mechanism by which lactobacillus treatment induces a positive effect on the GEC barrier
function, even in the presence of HIV-1, remains to be examined. However, it is well established
that HIV-1 binds to TLR-2 and TLR-4, thus activating the MAPK, PI3K, and NF-κB transcriptional
pathways, resulting in up-regulation of proinflammatory cytokines [12,51]. Subsequently, the increased
proinflammatory cytokines result in further activation of myosin light chain kinase (MLCK) and
myosin light chain (MLC) phosphorylation and cytoskeleton contraction, which induce delocalization
of ZO-1 from tight junctions, thus causing disassembly junctional proteins [11,52]. This damage to
barrier function allows pathogens to cross the epithelium. In vitro studies using intestinal epithelial
cells suggests that lactobacilli increase barrier function via tight-junction protein expression mediated
by the TLR-2 pathway [53]. The finding that L. reuteri RC-14 better maintained ZO-1 lattice structure
countering HIV-1’s effect on the protein again supports the protective properties of lactobacilli.
Although both E2 and MPA appeared to have anti-inflammatory effects in our in vitro experiments,
the mechanism underlying this effect and the outcomes of the two hormone treatments may be
very different in the context of HIV-1 transmission. E2 has been shown in other cells to exert its
anti-inflammatory effects through ERα and downregulation of NFkB-p65 expression [54]. E2 has also
been shown in a number of studies to protect against HIV-1 and other STIs [3,13,55]. DMPA on the
other hand has been shown to exert overall immunosuppressive effect through the GR receptor. Other
studies have shown that that MPA treatment of primary endometrial GECs significantly upregulated
genes for CCL20 and CXCL8 chemokines but did not lead to differential expression of genes related
to the classical inflammatory cytokines [25]. A dichotomized effect of MPA were seen in our current
studies where it enhanced barrier leakage significantly, while still exerting anti-inflammatory effects.
Thus, while E2 was correlated with truly beneficial effects overall on GECs, MPA in our study appeared
to have a mixed effect and is unlikely to enhance the overall protection against HIV-1. This is
supported by previous studies that have shown that women using DMPA are at higher risk of HIV-1
acquisitions compared to women not using any HC [19,21–25]. These studies show that MPA increases
chemokine (RANTES) levels resulting in enhanced recruitment of target cells, as well as increasing
expression of HIV-1 co-receptors such as CCR5 and CXCR4. Thus, despite its anti-inflammatory effect,
the increased barrier leakage combined with presence of more target cells and increased expression of
HIV-1 co-receptors likely contribute to increased HIV-1 susceptibility in women using DMPA [18,56].
Overall, our study provides a rationale to test a combination of E2 with probiotic Lactobacillus
to enhance vaginal epithelial barrier function, decrease inflammation, and potentially lower HIV-1
acquisition, replication and shedding. These results provide clear insight into how factors in the genital
microenvironment can affect HIV-1 acquisition and will subsequently assist in the development of
prophylactic strategies to reduce HIV-1 transmission.
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